Registry for patients with moderate-to-severe atopic dermatitis in Switzerland

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to create a national registry for patients suffering from moderate-to-severe atopic dermatitis (AD) in Switzerland. It will document the medical care provided to these patients, assess the appropriateness of care, and evaluate the psychosocial impact of AD. The study will include children aged 12 and older, adolescents, and adults, who will be followed for at least 24 months to gather comprehensive data on their treatment and outcomes. The registry will also facilitate research into risk factors and comorbidities associated with AD.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 12 years
* AD according to the UK Working Party's Diagnostic Criteria (28)
* Moderate to severe AD as defined by
* objective SCORAD \> 20 or IGA ≥ 3 (moderate) or
* currently on systemic antiinflammatory therapy for AD or
* previous systemic antiinflammatory therapy for AD within past 24 months

Exclusion Criteria:

* refusal to sign the informed consent form

Where it's running

• Universitätsspital Basel, Allergologie
  Basel, Switzerland Recruiting
• Inselspital, Department of Dermatology
  Bern, Switzerland Recruiting
• Dermatology & Skin Care Clinic
  Buochs, Switzerland Recruiting
• HFR Hôpital Cantonal de Fribourg
  Fribourg, Switzerland Recruiting
• Dermatologie CHUV
  Lausanne, Switzerland Recruiting
• Kantonsspital St. Gallen - Klinik für Dermatologie, Venerologie und Allergologie
  Sankt Gallen, Switzerland Recruiting

Study contacts

• Principal investigator: Dagmar Simon, Prof. Dr. med. — Department of Dermatology, Inselspital
• Study coordinator: Dagmar Simon, Prof. Dr. med.
• Email: dagmar.simon@insel.ch
• Phone: +41 31 632 22 78

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Roflumilast Cream 0.3% for moderate to severe atopic dermatitis in children, adolescents, and adults

  A cream called roflumilast 0.3% is tested once daily to see if it helps people with moderate to severe atopic dermatitis, compared to a non-medicated cream, across ages 6 and up.

  Recruiting at 4 sites Phase 3 Arcutis Biotherapeutics, Inc. · Birmingham, Alabama and 3 other locations · NCT07916480

• Nocturnal ScratchSense ring: test of automatic scratch detection in adults with itchy skin

  This study tests whether the Replior ScratchSense ring can accurately detect and measure nighttime scratching in adults with itchy skin conditions.

  Recruiting Replior AB · Grenoble · NCT07909967

• ADBest TREAT Registry for adults with atopic dermatitis

  A registry in Germany is collecting real-world data from adults with atopic dermatitis to see how treatments are used and how the disease affects quality of life.

  Recruiting Universitätsklinikum Hamburg-Eppendorf · Hamburg · NCT07904546

• How lebrikizumab affects the skin microbiome and mycobiome in adults with atopic dermatitis

  This study looks at whether lebrikizumab changes the skin bacteria, fungi, and specifically Staphylococcus species, in adults with moderate-to-severe atopic dermatitis.

  Recruiting University Hospital Bispebjerg and Frederiksberg · Copenhagen · NCT07807228

• QX-4533 safety study in healthy volunteers and people with moderate-to-severe atopic dermatitis

  This study tests the safety and tolerability of QX-4533, given as a pill, in healthy adults and in patients with moderate-to-severe atopic dermatitis to see how the drug behaves in the body and what side effects may occur.

  Recruiting Phase 1 QuantX Biosciences US Inc. · Shanghai, Shanghai Municipality · NCT07800104

• Tilrekimig for moderate-to-severe eczema in teens and adults

  A 52-week study will test tilrekimig against dupilumab and a placebo to see if it helps people 12 and older with moderate-to-severe atopic dermatitis.

  Recruiting at 31 sites Phase 3 Pfizer · Birmingham, Alabama and 49 other locations · NCT07783425

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.